Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside

{固定描述} This analysis evaluates Johnson & Johnson’s (JNJ) recently FDA-approved Icotyde psoriasis treatment, co-developed with clinical-stage biotech Protagonist Therapeutics (NASDAQ: PTGX), and the associated implications for both JNJ’s dermatology portfolio growth and broader bullish positioning among eli

Live News

Published April 27, 2026, 14:07 UTC – Institutional investment tracker Insider Monkey released its latest survey of top hedge fund holdings on Monday, revealing that billionaire investor Joe Edelman has ranked Protagonist Therapeutics (PTGX) 10th on his list of 10 high-upside stock picks, driven largely by the biotech’s de-risked commercial partnership with Johnson & Johnson (JNJ) around the recently FDA-approved Icotyde for moderate-to-severe plaque psoriasis. Icotyde, the first and only once-d Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside{随机描述}{随机描述}Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside{随机描述}

Key Highlights

Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside{随机描述}{随机描述}Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside{随机描述}

Johnson & Johnson (JNJ) – Icotyde Partnership Drives Portfolio Expansion and De-Risked Biotech Upside - {财报副标题}

Live News

Key Highlights

Expert Insights